Literature DB >> 20445577

BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.

B A Burke1, M Carroll.   

Abstract

The role of the BCR-ABL oncogene in the progression of chronic myeloid leukemia (CML) to blast crisis (BC) is unknown. The appearance of chromosomal aberrations in patients with CML BC has led to many attempts to elucidate a mechanism whereby BCR-ABL affects DNA damage and repair. BCR-ABL-expressing cells have been found to accumulate genetic abnormalities, but the mechanism leading to this genomic instability is controversial. In this study, we review the effects of BCR-ABL on DNA repair mechanisms, centrosomes, checkpoint activation and apoptosis. BCR-ABL has diverse effects on these mechanisms, but which of these effects are necessary for the progression of CML to BC is still unresolved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20445577      PMCID: PMC4425294          DOI: 10.1038/leu.2010.67

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  60 in total

1.  Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins.

Authors:  Nicola Brady; Terry J Gaymes; Manyee Cheung; Ghulam J Mufti; Feyruz V Rassool
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

2.  The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells.

Authors:  M Sattler; S Verma; G Shrikhande; C H Byrne; Y B Pride; T Winkler; E A Greenfield; R Salgia; J D Griffin
Journal:  J Biol Chem       Date:  2000-08-11       Impact factor: 5.157

3.  BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress.

Authors:  M Koptyra; K Cramer; A Slupianek; C Richardson; T Skorski
Journal:  Leukemia       Date:  2008-04-10       Impact factor: 11.528

Review 4.  BCR/ABL, DNA damage and DNA repair: implications for new treatment concepts.

Authors:  Tomasz Skorski
Journal:  Leuk Lymphoma       Date:  2008-04

5.  Rejoining of DNA double-strand breaks in vitro by single-strand annealing.

Authors:  B Göttlich; S Reichenberger; E Feldmann; P Pfeiffer
Journal:  Eur J Biochem       Date:  1998-12-01

6.  Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase.

Authors:  H F Salloukh; P Laneuville
Journal:  Leukemia       Date:  2000-08       Impact factor: 11.528

7.  High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.

Authors:  Stephanie G Willis; Thoralf Lange; Shadmehr Demehri; Sandra Otto; Lucy Crossman; Dietger Niederwieser; Eric P Stoffregen; Shannon McWeeney; Ines Kovacs; Byung Park; Brian J Druker; Michael W Deininger
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

8.  High Bcr-Abl expression prevents the translocation of Bax and Bad to the mitochondrion.

Authors:  K Keeshan; T G Cotter; S L McKenna
Journal:  Leukemia       Date:  2002-09       Impact factor: 11.528

9.  The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein.

Authors:  N Takeda; M Shibuya; Y Maru
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

10.  Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks.

Authors:  Annahita Sallmyr; Alan E Tomkinson; Feyruz V Rassool
Journal:  Blood       Date:  2008-06-04       Impact factor: 22.113

View more
  22 in total

1.  Genomic instability in chronic myeloid leukemia: targets for therapy?

Authors:  N Muvarak; P Nagaria; F V Rassool
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

2.  Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.

Authors:  Kamalika Moulick; James H Ahn; Hongliang Zong; Anna Rodina; Leandro Cerchietti; Erica M Gomes DaGama; Eloisi Caldas-Lopes; Kristin Beebe; Fabiana Perna; Katerina Hatzi; Ly P Vu; Xinyang Zhao; Danuta Zatorska; Tony Taldone; Peter Smith-Jones; Mary Alpaugh; Steven S Gross; Nagavarakishore Pillarsetty; Thomas Ku; Jason S Lewis; Steven M Larson; Ross Levine; Hediye Erdjument-Bromage; Monica L Guzman; Stephen D Nimer; Ari Melnick; Len Neckers; Gabriela Chiosis
Journal:  Nat Chem Biol       Date:  2011-09-25       Impact factor: 15.040

Review 3.  JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?

Authors:  Linda M Scott; Vivienne I Rebel
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

4.  Loss of mutL homolog-1 (MLH1) expression promotes acquisition of oncogenic and inhibitor-resistant point mutations in tyrosine kinases.

Authors:  Lorraine Springuel; Elisabeth Losdyck; Pascale Saussoy; Béatrice Turcq; François-Xavier Mahon; Laurent Knoops; Jean-Christophe Renauld
Journal:  Cell Mol Life Sci       Date:  2016-07-19       Impact factor: 9.261

5.  Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.

Authors:  W Wang; J E Cortes; P Lin; J D Khoury; D Ai; Z Tang; G Tang; J L Jorgensen; L J Medeiros; S Hu
Journal:  Leukemia       Date:  2015-04-14       Impact factor: 11.528

6.  ETV6/RUNX1 induces reactive oxygen species and drives the accumulation of DNA damage in B cells.

Authors:  Hans-Peter Kantner; Wolfgang Warsch; Alessio Delogu; Eva Bauer; Harald Esterbauer; Emilio Casanova; Veronika Sexl; Dagmar Stoiber
Journal:  Neoplasia       Date:  2013-11       Impact factor: 5.715

7.  Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia.

Authors:  Artur Slupianek; Yashodhara Dasgupta; Shu-Yue Ren; Ewa Gurdek; Milene Donlin; Margaret Nieborowska-Skorska; Fabrice Fleury; Tomasz Skorski
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

8.  A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis.

Authors:  Katsuya Sakai; Yuichi Ishikawa; Yumiko Mori; Miki Kobayashi; Chisako Iriyama; Yukiyasu Ozawa; Tatsuya Suzuki; Yosuke Minami; Kazuhiro Ishikawa; Norio Kaneda; Tomoki Naoe; Hitoshi Kiyoi
Journal:  Int J Hematol       Date:  2011-01-25       Impact factor: 2.490

9.  Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor.

Authors:  Sabyasachi Bhattacharya; Hui Zheng; Christos Tzimas; Martin Carroll; Darren P Baker; Serge Y Fuchs
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

Review 10.  Multidrug-resistant cancer cells and cancer stem cells hijack cellular systems to circumvent systemic therapies, can natural products reverse this?

Authors:  Qian Zhang; Yunjiang Feng; Derek Kennedy
Journal:  Cell Mol Life Sci       Date:  2016-09-12       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.